Chapter 141: Put some pressure on the Germans (please subscribe)
Back at Qingshan Pharmaceutical, Zhang Yang quickly found the contact information of Hans, the vice president of BI Company, on his mobile phone.
This is from my previous participation in the "Global Kidney Disease Summit".
After thinking for a moment, he typed:
"President Hans, can you receive my message?"
After the message was sent via WhatsApp (similar to WeChat abroad), Hans responded quickly.
"Zhang, I am very happy to receive news from you."
Zhang Yang felt relieved and then tried:
"Hans, I paid attention to your company before The 'BI-Toxin Filtration Catalyst' promoted at the 'Kidney Summit' has completed its first phase of clinical trials. I am very interested."
"I wonder if we can have some cooperation or transactions. ?”
"Cooperation? Deal?"
Hans' reply came quickly, along with a surprised expression, which was obviously a bit unexpected.
Zhang Yang continued to test:
"Yes, I think the clinical phase 1 data released by your company is not very good. If there is an idea of trading patents, I would be somewhat interested, you know Yes, we also have research and development projects related to kidney dialysis.”
“Of course, cooperation is also possible.”
This time Hans was sure that Zhang Yang was serious. About a minute later, his message replied:
“We are indeed in a little trouble now, but the company currently does not trade the ‘Toxin Filtration Catalyst’ patent. Idea, but I can help you submit it to the president for the cooperation you mentioned. You know, I can’t make the decision on this kind of thing.”
"By the way, how do you want to cooperate? Shall we work together to develop a 'toxin filtration catalyst'?"
This reply is not surprising to Zhang Yang. As Fang Hanliang said before, it is impossible for BI Company to If the clinical phase 1 data is not as good as expected, the patent will be sold immediately. At least it will take a while to find out that there is really little hope before we can find a way to deal with it.
As for the cooperation plan, he has actually already thought about it.
The "toxin filtering catalyst" developed by BI Company is specially used in extracorporeal dialysis machines and needs to be used in conjunction with the dialysis machines.
What he wanted to obtain was not this drug, but the active pharmaceutical ingredients that could decompose macromolecular toxins.
He hopes to obtain a patent for compounds that can decompose macromolecular toxins and drugs, and then use this to develop pharmaceuticals that can directly enter the human body to decompose and crush macromolecular toxins and drugs in the human body.
Finally, use the "Kidney Toxin Clearing Dialysis Needle" to expel small molecule toxins from the body, thereby improving the toxin clearance rate.
It can be said that these are two completely different technical routes from BI's "toxin filtering catalyst".
"No, we are not cooperating in the research and development of 'Toxin Filtration Catalyst'. We will not participate in your research and development progress. We only hope to obtain the patent authorization of this drug."
"To put it simply...we plan to Conduct secondary research and development on the basis of the patent of this drug and develop a new drug.”
"So, we hope to obtain a permanent buyout of the patent authorization."
"As for the patent authorization fee, we are willing to pay 50 million U.S. dollars, equivalent to RMB 350 million."
Hans soon Understanding what Zhang Yang meant, patent licensing transactions are actually a very common business model in the pharmaceutical field.
To put it simply, the original patent is still owned by BI Company, but Qingshan Pharmaceutical can conduct research and development based on this patent.
As for whether drugs can be developed, or how dividends will be paid after patents are used to develop new drugs, this can all be discussed slowly and in detail.
"Okay, Zhang, I can help you ask the president about this."
"Okay, thank you."
Zhang Yang ended the call , feeling slightly relieved.
To be honest, he was not completely sure about this transaction, and the next step would only depend on the BI company's decision.
On the other side,
Tall, thin, with blond hair, young Hans quickly came to the office of President Marcus Duesmann.
President Dusman is in his fifties and is a typical German. Apart from the dark wood desk and the wooden clock hanging on the wall, there is almost nothing else in his office. decorations.
Even the shape of the desk is square and square, with an extremely rigorous solemnity and solemnity.
The desktop of the desk is always spotless, and all documents are meticulously and neatly arranged, just like the impression that President Dusman gives people - rigorous, even a little old-fashioned.
Every time Hans walked into the office, he had an indescribable seriousness. When he saw President Dusman handling documents attentively, he walked up to him and said respectfully:
"Mr. President , to bother you, I just received a business inquiry about our 'BI-Toxin Filtration Catalyst' Business transaction inquiry, so I came here to report to you.”
“Zhang Yang, the boss of Huaxia Qingshan Pharmaceutical, is very interested in our patent of ‘Toxin Filtration Catalyst’, and he wants to seek a patent buyout or a deal. Let’s cooperate.”
“Buy out the patent?”
President Dusman slowly put down the document in his hand and shook his head:
"It is impossible to buy out the patent. Although our 'BI-Toxin Filtration Catalyst' has encountered a little trouble, we are not short of This little money.”
“Well, that’s what I told Qingshan. Pharmaceutical industry, so they proposed cooperation. "
"To put it simply, they hope to obtain the patent authorization of our 'BI-toxin filtering catalyst', and then conduct secondary research and development based on our patent. Develop new drugs. ”
New drugs?
Dusman frowned slightly, but after a moment, he shook his head again:
"Hans, I am not interested in their proposal to purchase patent licenses. I think the most important thing we should do now is to focus on For the drug research and development of our 'BI-Toxin Filtration Catalyst', rather than commercial cooperation." Hans was slightly taken aback.
To be honest, as a young vice president, he is not opposed to business cooperation with other pharmaceutical companies.
After all, the current mainstream of the pharmaceutical market is the prevalence of BD trading. We have me among you, and you among me. We pay attention to sharing risks and making money together.
Moreover, the cooperation proposed by Qingshan Pharmaceutical this time is not to buy out the patent, and it will not even have any conflict with the "BI-toxin filtration catalyst" currently developed by the company...
I did not expect such a situation. President Dusman refused without even asking the price.
"Mr. President, they have offered a price of 50 million US dollars..."
"If you think it is too low, we can talk to them again and even increase the price. Proportional dividends for some new drugs!”
“After all, cooperating with them will not affect the normal research and development of our ‘BI-Toxin Filtration Catalyst’, and we can also get a good amount of funds.”
"No, it's not necessary."
Dusman shook his head again and decisively refused.
For him, he does not like this kind of business cooperation very much, but prefers to devote all his energy to the research and development of drugs and make money through drugs.
After finishing speaking, he did not forget to remind:
“Hans, you should pay more attention to the progress of the R&D team and find new drugs as soon as possible. Why is there only a 2-3% effective clearance rate? ”
Hans pouted helplessly:
“Okay, Mr. President, then I will reply to Qingshan Pharmaceutical truthfully.”
……
“Zhang, I I reported it to Mr. President for you, but Mr. President refused.”
“Oh, do you think the price is too low?”
"No, Mr. President has no interest in cooperation at all. We prefer to focus on drug research and development rather than commercial cooperation."
Zhang Yang quickly received a reply from Hans. For this reason, he Some surprises are reasonable.
In the markets of developed countries around the world, German pharmaceutical companies conduct the fewest BD transactions every year, and the number of transactions is only one-tenth of that in the United States.
You can call them conservative, or you can call them old-fashioned, but this seems to be the preference engraved in their genes.
However, such a result made Zhang Yang feel a little desperate. BI Company's lack of intention to cooperate meant that it could not obtain the patent for the "toxin filtering catalyst", and it would not be able to develop any effect on this basis. catalyst for the human body.
"What should I do?"
Zhang Yang's mind was racing, and the situation was gradually becoming clear. He could no longer wait for the BI company to change his mind.
The only way...
Put more pressure on the Germans.
Zhang Yang's eyes lit up, BI Company developed the "BI-Toxin Filtration Catalyst" after all to make money. After all, it was not to generate electricity for love, but really wanted to sell it on the market.
If a competing product similar to "BI-Toxin Filtration Catalyst" appears at this time, BI Company will definitely feel tremendous pressure.
No matter how stubborn the Germans are, they will start to seriously measure market prices under pressure, evaluate the market prospects if they are developed slowly, and truly consider whether to engage in commercial cooperation to reduce risks!
“This competitor can be taken on by Tsingshan Pharmaceutical. With Tsingshan Pharmaceutical’s current international reputation, it can definitely put pressure on the Germans.”
“Besides, it’s true. Fake, this plan not only puts pressure on the Germans, but on the other hand, we really need to start drug research and development in the field of 'macromolecule toxin catalysts'!"
Thinking about it, Zhang Yang's ideas became clearer.
"In addition to this, we must also start to conduct more in-depth research on the 'BI-toxin filtering catalyst'."
"At present, we do not know the specific situation of the 'BI-toxin filtering catalyst'. It is still uncertain whether it will be effective when combined with the 'Kenduqing Dialysis Injection', which will affect our subsequent price evaluation of the drug patent. . ”
“Only by doing enough homework and truly understanding the effect of ‘BI-Toxin Filtration Catalyst’ can we know whether it is worth pursuing it and how much it is worth to buy it out. ”
Thirty minutes later, a blank notebook page was filled with Zhang Yang’s plan. After careful consideration again, he called Fang Hanliang.
Fang Hanliang is not in a hurry to set up a project these days. He has been checking the team member information of the R&D center to form his own R&D team.
That's just right.
"Fang Bo, to make a long story short, you know that I am very interested in BI Company's 'Toxin Filtration Catalyst'."
"Today I contacted their Vice President Hans and expressed the hope of cooperation. , but they refused directly."
"I have a task for you now. I want to imitate the 'BI-toxin' as soon as possible. I want to know if the 'Toxin Filtering Catalyst' combined with 'Kendu Qing' is effective! If so, what kind of effect can it achieve?"
"In addition, We cannot pin all our hopes on BI Company, we need to develop a similar catalyst that can decompose macromolecular toxins. ”
Fang Hanliang understood it as soon as he heard it, and his face suddenly turned bitter:
"Mr. Zhang, this is not one task, you have two tasks."
There are a total of 500 monthly passes for National Day. , added 5 chapters, owed -1 chapter, and currently owes 5 chapters
(End of this chapter)